Acrosian LLC was founded in 2026 and is headquartered in the United States, with operations across India and Europe. The company was established by the founding team that previously built and scaled Quartesian — one of the largest independent biometrics CROs in the industry, growing to approximately 600 staff with operations across three continents before a successful exit to private equity, which occurred when Quartesian became part of Veranex in 2021.

The company’s leadership comprises Benjamin Jackson (Chairman), Soumitra Chowdhury (CEO), Vladimir Mats (Chief Commercial Officer), and Yurii Kartashov, PhD (Chief Research and Development Officer). The founders collectively bring over two decades of biometrics CRO leadership experience at scale, spanning every phase of clinical development across pharmaceutical, biotechnology, and medical device sectors.

Acrosian’s founding rationale is explicitly generational: rather than retrofitting artificial intelligence onto an existing large-scale CRO infrastructure, the leadership team made a deliberate decision to restart from a clean foundation, building AI augmentation into the operational and quality architecture of the firm from inception. The company describes its approach through a three-principle model: senior judgment applied by experienced biometrics professionals, AI leverage applied selectively and progressively across workflows, and a validation gate requiring every AI-augmented process to meet GxP requirements before deployment. The company targets both emerging biotechs and established global pharmaceutical organisations, and operates a deliberately lean, senior-led team model.

Key Products and Services

Integrated Biometrics Execution

A unified biometrics delivery service spanning all four core functions under a single delivery model, quality system, and audit trail:

• Clinical Data Management — protocol-aligned database design, eCRF build, data cleaning, query management, medical coding (MedDRA and WHO Drug), and database lock readiness, delivered under senior data manager oversight
• Biostatistics — statistical analysis plan (SAP) development, sample size and power calculations, randomisation design, interim analyses, adaptive design strategy, and regulatory submission support, delivered under senior statistician oversight
• Statistical Programming — SDTM and ADaM dataset development, Tables, Listings and Figures (TLF) generation, submission-ready CDISC outputs, define.xml, and regulatory package preparation, delivered under senior programmer oversight
• Medical Writing — clinical study protocols, clinical study reports (CSRs), regulatory briefing books, submission-ready regulatory documents, and integrated summary preparation, delivered under senior medical writer oversight

AI Enablement Services

An advisory and implementation service offered selectively to sponsors and CROs evaluating or deploying AI within clinical and biometrics workflows:

• AI Landscape and Readiness Assessment — independent evaluation of AI tooling options against client-specific workflows, regulatory exposure, and operational maturity
• AI Implementation — selection, configuration, and deployment of AI tools into biometrics workflows under senior expert oversight
• GxP Validation Frameworks — development of Computer System Validation (CSV) documentation, SOPs, and audit-ready process architecture for AI-augmented workflows under 21 CFR Part 11 and ICH E6(R3)
• Senior Advisory — ongoing engagement for sponsor and CRO leadership navigating AI adoption in regulated clinical environments

Acrosian occupies a clearly defined and deliberately narrow position in the CRO landscape: a senior-led, biometrics-only CRO that has designed AI augmentation into its operating model from inception rather than as a retrofit to legacy infrastructure. This distinction matters in a market where most CROs — large and small — are attempting to integrate AI tools into organisations built for a headcount-driven delivery paradigm, creating well-documented friction around validation, accountability, and quality system alignment. The founding team’s track record at Quartesian — scaling a biometrics-only CRO to 600 staff across three continents before a private equity exit — provides a credibility foundation that new entrants typically lack, and their stated cultural commitment to avoiding workforce reductions across nearly two decades of prior operations signals an operational philosophy that may resonate with sponsors concerned about staff continuity and institutional knowledge. The company’s lean, senior-only team model represents both a differentiation and a capacity constraint in the near term; its long-term trajectory will depend on whether its AI-augmented delivery model can deliver the throughput and scalability that the market expects at a quality standard that satisfies regulatory scrutiny.